Hydrocortisone Panpharma (Hydrocortisone Sodium Succinate)

Hydrocortisone Panpharma is indicated for several acute medical situations that need rapid glucocorticoid effect.

• Treatment of adrenal insufficiency and adrenal crisis
• Management of severe allergic reactions, including anaphylaxis
• Control of acute inflammatory conditions such as asthma exacerbations or severe dermatitis
• Replacement therapy in congenital adrenal hyperplasia when oral agents are unsuitable
• Short‑term control of postoperative inflammation when oral administration is not feasible

• Hydrocortisone sodium succinate is a pro‑drug that is rapidly converted to active hydrocortisone after intramuscular or intravenous injection. The active molecule binds to intracellular glucocorticoid receptors, translocates to the nucleus, and modulates gene transcription. This up‑regulates anti‑inflammatory proteins (e.g., annexin‑1) and suppresses pro‑inflammatory cytokines such as IL‑1, IL‑6, and TNF‑α, resulting in reduced leukocyte migration, vascular permeability, and immune activation.

Like other systemic glucocorticoids, Hydrocortisone Panpharma may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common

• Transient elevation of blood glucose levels, usually self‑limited
• Injection‑site pain, erythema, or mild swelling
• Headache, insomnia, or mild mood changes

Serious

• Severe hyperglycemia or diabetic ketoacidosis, especially in diabetic patients
• Acute adrenal insufficiency after abrupt discontinuation of therapy
• Anaphylactic or severe hypersensitivity reactions, including angio‑edema
• Significant infection or reactivation of latent infections such as tuberculosis
• Osteonecrosis or avascular necrosis with prolonged high‑dose exposure

Hydrocortisone Panpharma should be used with caution in patients who have certain conditions.

• Documented hypersensitivity to hydrocortisone or any excipients in the formulation
• Uncontrolled diabetes mellitus or marked hyperglycemia
• Active systemic infections, including viral, bacterial, or fungal etiologies
• Osteoporosis, history of fractures, or other bone‑weakening disorders
• Underlying psychiatric conditions such as depression, psychosis, or severe anxiety
• Pregnancy or breastfeeding (risk to fetus/infant not well established)
• Concomitant use of other immunosuppressive agents that may increase infection risk

Hydrocortisone Panpharma can interact with several drug classes; awareness of these interactions helps minimize adverse outcomes.

Avoid

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) that may reduce glucocorticoid exposure
• Live vaccines, because immunosuppression can diminish vaccine efficacy and increase infection risk
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that raise the chance of gastrointestinal bleeding

Use with caution

• Anticoagulants such as warfarin, as glucocorticoids may alter INR values
• Antidiabetic agents (insulin, oral hypoglycemics) because hyperglycemia may be exacerbated
• Other systemic corticosteroids, which can lead to additive immunosuppression and metabolic effects
• Azole antifungals (e.g., ketoconazole, itraconazole) that inhibit glucocorticoid metabolism
• Diuretics, which may potentiate electrolyte disturbances